S-1 · primary offering
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
BIVI$1.71+24.45%
Biovie Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$14.55M
Float & O/S:
Inst Own:
DilutionScan read 17 of BIOVIE INC.'s SEC filings and found 18 warrant series, 1 convertible, 2 ATM programs, 2 shelf registrations, 3 S-1 registrations and 2 completed offerings on file for BIVI. The latest dilution event on file is ATM sales on Sep 11, 2026. Analysis updated Sep 17, 2026.
Signal8 Summary
2h old
BIVI
Going-concern warning, cash critically low
- Business
- WeakNo revenue, $22.1M net loss, going-concern warning
- Stock risk
- High$12.1M micro-cap, shares +390% YoY, 134% dilution overhang
Snapshot
BioVie is a clinical-stage biotech with no revenue, testing bezisterim in Parkinson's, Alzheimer's and Long COVID, plus a cirrhosis drug in earlier testing.
What's Happening Right Now
- : On Nov 2, 2026, BioVie was invited to give a late-breaking presentation on bezisterim Long COVID data in Nice, France; the company's own disclosure notes the trial missed statistical significance in the overall patient population, with gains limited to pre-specified high-symptom subgroups.
- : BioVie was invited to present ADDRESS-LC Long COVID data at an NIH RECOVER-TLC workshop on Nov 5, 2026, again noting the overall trial population missed significance on all endpoints while pre-specified subgroups showed significant gains.
- : On Oct 20, 2026, BioVie presented Phase 2b SUNRISE-PD results at the American Neurological Association meeting showing bezisterim significantly improved motor and non-motor symptoms in a high-inflammation subgroup of the 57-patient trial, a result the company calls exploratory ahead of a larger confirmatory trial.
- : On Oct 19, 2026, BioVie reported that bezisterim's Long COVID benefits were concentrated in patients with severe baseline fatigue, PEM or cognitive impairment, with the overall intent-to-treat population only trending toward improvement in the 203-patient ADDRESS-LC trial.
- : On Sep 11, 2026, BioVie set up an at-the-market program to sell up to $6.46M of stock through A.G.P./Alliance Global Partners, disclosing that full use could add roughly 3.1 million shares to the then-8.53 million outstanding and flagging substantial-dilution and Nasdaq delisting risk.
- : Registered 16.03M shares for sale on Form S-1.
- : Registered $300.00M of securities for sale on Form S-3.
- : Raised $12.00M in gross proceeds through a public offering, with warrants over 7.35M shares.
Raise routes on file: active ATM + effective shelf + pending S-1 + effective S-1 · latest dilution event 53 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Sep 11, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Filed
S-1 · primary offering
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · resale registration
Proposed maximum
Shares registered
- Filed
- Effective
August 2025 Public Offering Warrants (BIVIW)
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
August 2025 Pre-Funded Warrants
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2026
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
ATM program
Issued 2022
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2023
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Public offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
ATM block sale
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your BIVI trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
